Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical) filed its Monthly Return for April 2026, confirming that both authorised and issued share capital were unchanged during the period.

Authorised Capital • Total authorised share capital stayed at HKD 1.00 billion, representing 100.00 billion ordinary shares with a par value of HKD 0.01 each.

Issued and Treasury Shares • Outstanding shares (excluding treasury) remained at 9.15 billion. • Treasury shares stood at 184.01 million, keeping total issued shares at 9.33 billion. • No shares were issued, repurchased, cancelled or transferred during the month.

Public Float • The company confirmed compliance with the Hong Kong Stock Exchange’s minimum 25% public-float requirement as of 30 April 2026.

Share Option Schemes • Two option tranches adopted on 24 October 2017 were unchanged: — 60.59 million options exercisable at HKD 0.972. — 7.50 million options exercisable at HKD 2.22. • No options were granted, exercised, cancelled or lapsed; therefore, no capital was raised in April.

Other Instruments • The issuer reported no warrants, convertibles, HDRs or other equity-linked instruments outstanding or transacted during the month.

Governance • The return was submitted on 4 May 2026 by Executive Director and Joint Company Secretary, Ms. Chen Yanling.

Overall, the April filing underscores a stable equity structure with full compliance to listing regulations and no dilution or treasury-share activity.